BRAFV600E/ABL2-IN-2

BRAFV600E/ABL2-IN-2 is a dual inhibitor targeting BRAFV600E and ABL2 kinases, with an IC50 of 0.088 μM for human-derived BRAFV600E and 0.3 μM for human-derived ABL2. It reduces phosphorylation levels of downstream ERK1/2 and CrkL in melanoma cells, decreases the expression of P-glycoprotein (P-glycoprotein), and induces G1 phase cell cycle arrest and apoptosis (Apoptosis) in melanoma cells. This compound is useful for research related to melanoma.